Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730871 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
A Phase 4 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 4
- Development phase
- 173
- Enrollment target
NCT02730871 is a Phase 4 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 173 participants.
The verdict
NCT02730871, a Phase 4 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 173 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension.
Interventions
- DRUG Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
- DRUG Brinzolamide/brimonidine vehicle
- DRUG Travoprost 0.004%/timolol 0.5% solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2016-06-24 |
| Est. Completion | 2018-07-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02730871
The ClinicalTrials.gov registry entry for NCT02730871 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension is the first listed.
NCT02730871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02730871 about?
NCT02730871 is a clinical study titled "Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®". The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT02730871?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 173 participants. The study started on 2016-06-24. Estimated completion is 2018-07-13.
What interventions are being tested in trial NCT02730871?
The interventions under investigation include: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension (DRUG), Brinzolamide/brimonidine vehicle (DRUG), Travoprost 0.004%/timolol 0.5% solution (DRUG).
Who is sponsoring clinical trial NCT02730871?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.